ClinicalTrials.gg
CompletedNCT03838133Updated Apr 7, 2020

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

A Phase 2 interventional study of TLC590 and Naropin® in Hallux Valgus, sponsored by Taiwan Liposome Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Taiwan Liposome Company · Phase 2, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Hallux Valgus with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Hallux Valgus · United States.

Enrollment
8th of 24
150 · median 86
Started
2019
with 3 others
Phase 2
3 of 32
1 open now
Registered
16th of 32
by date

Among the 32 studies in Hallux Valgus with a site in United States, this one is the 8th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2019, is one of 3 in phase 2, and was the 16th registered.

Hallux Valgus

157 studies on the registry are indexed under Hallux Valgus; 36 are open to participants now.

Browse Hallux Valgus studies →

Open to participants now

5 of the 32 studies in Hallux Valgus with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Hallux Valgus studies recruiting now, 10 (48%) set no upper age limit and 7 (33%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Hallux Valgus with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, 2-part comparator- and placebo-controlled study to evaluate the safety, PK, and efficacy of TLC590 via a single infiltrative local administration in adult subjects following bunionectomy.

Read the detailed description

This is a Phase 2, randomized, double-blind, 2-part comparator- and placebo-controlled study to evaluate the safety, PK, and efficacy of TLC590 via a single infiltrative local administration in adult subjects following bunionectomy.

The primary objective of this study is to evaluate the analgesic efficacy of TLC590 for post-surgical pain management in subjects following bunionectomy.

The secondary objectives of this study are:

  • To evaluate the pharmacokinetic (PK) profile and dose-exposure relationship of TLC590, as well as the bioavailability as compared with Naropin®.
  • To evaluate the safety and tolerability of TLC590 for post-surgical pain management in subjects following bunionectomy.
  • To evaluate the exposure-response relationship between PK parameters and pain intensity.

The study will be divided into two parts:

Part 1: Blinded Pharmacokinetics of TLC590 and Naropin®. Approximately 48 subjects will be randomized to treatments.

Part 2: Efficacy and Safety of TLC590 versus bupivacaine and Placebo. Part 2 of the study will randomize approximately 150 evaluable subjects who meet all entry criteria.

03

Conditions studied

  • Hallux Valgus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Male or female between 18 and 65 years of age.
  3. ≤ 35 kg/m2.
  4. Mild to moderate hallux valgus deformity.
  5. Scheduled to undergo a primary, unilateral first metatarsal bunionectomy repair under local anesthesia.
  6. American Society of Anesthesiology Physical Status Classification of 1 or 2 at screening.
  7. Female subjects are eligible only if all of the following apply:

    • Not pregnant;
    • Not lactating;
    • Not planning to become pregnant during the study;
    • Commits to the use of an acceptable form of for the duration of the study and for 42 days from administration of study drug.
  8. Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control, for the duration of the study until at least 1 week after the administration of study medication.

Exclusion criteria

Exclusion Criteria:

  1. abnormal clinical laboratory test value.
  2. Evidence of a clinically significant 12-lead abnormality.
  3. History or evidence of orthostatic hypotension, syncope or other syncopal attacks.
  4. History or clinical manifestations of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study.
  5. A history of seizure disorder or currently taking anticonvulsants.
  6. History of to ropivacaine, any other amide-type local anesthetic, propofol, lidocaine, midazolam, acetaminophen, naproxen, morphine or oxycodone (or other opioids).
  7. Concurrent painful physical condition that may confound post-operative pain assessments.
  8. Persistent or recurrent nausea and/or vomiting due to other etiologies.
  9. History of severe or post-operative nausea or vomiting (PONV) deemed clinically significant.
  10. History of alcohol abuse or prescription/illicit drug abuse within 2 years.
  11. Current evidence of alcohol abuse within 6 months.
  12. Received opioid therapy for longer than 4 days per week within 2 months or opioid use within 2 weeks.
  13. Use of concurrent therapy that could interfere with the evaluation of efficacy or safety.
  14. Unable to discontinue medications that have not been at a stable dose for at least 14 days prior to the study surgical procedure, within 5 half-lives of the specific prior medication.
  15. Use of any of the following medications within 5 half-lives or as specified prior to the study surgical procedure:

    • Low-dose aspirin therapy for cardiovascular protection
    • Class III antiarrhythmic drugs
    • Strong CYP1A2 inhibitors
    • CYP1A2 substrates
    • Strong inhibitors
    • , either systemically, inhaled either intranasally or orally, or by intra-articular injection, or NSAIDs within 14 days
    • Any product within 30 days.
  16. Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
  17. History or positive test results for ; active or C.
  18. Contralateral foot bunionectomy in the last 3 months or have collateral procedures.
  19. in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  20. History of rheumatoid disease, Type 1 or Type 2 diabetes or peripheral circulatory disorders.
  21. Documented sleep apnea or are on home continuous positive airway pressure.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    TLC590 dose 1 (152 mg)

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Experimental
    TLC590 dose 2 (190 mg)

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Experimental
    TLC590 dose 3 (228 mg)

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Active comparator
    Naropin®

    Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)

    Drug: Naropin®

  • Placebo comparator
    Placebo

    Normal Saline (0.9% sodium chloride, 10 mL)

    Drug: Normal Saline

  • Active comparator
    Bupivacaine

    Bupivacaine HCl 50 mg (0.5%, 10 mL)

    Drug: Bupivacaine

Interventions

  • DrugTLC590

    TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients

    Also known as: TLC590 (Ropivacaine Liposome Injectable Suspension)

  • Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)

    Also known as: Naropin, 0.5% Injectable Solution

  • DrugNormal Saline

    Normal Saline (0.9% sodium chloride, 10ml)

    Also known as: Saline

  • Bupivacaine 50 mg (0.5%, 10 mL)

06

What researchers measure

Primary outcomes

  1. AUC of numerical pain rating scale

    AUC of numerical pain rating scale (NPRS-R) following bunionectomy surgery

    Time frame: 0-24 hours, 0-72 hours

Secondary outcomes

  1. PK Cmax

    Maximum blood concentration (Cmax)

    Time frame: 0-168 hours

  2. PK Tmax

    Time to reach maximum blood concentration (Tmax)

    Time frame: 0-168 hours

  3. PK t½

    Terminal elimination half-life (t½)

    Time frame: 0-168 hours

  4. PK AUC

    Area under the blood concentration-time curve (AUC)

    Time frame: 0-24, 0-48 , 0-72, 0-96 hours

  5. Number of treatment emergent adverse event (TEAE)

    Number of treatment emergent adverse event (TEAE) occurred in the study

    Time frame: Screening through Day 43

  6. Electrocardiogram (RR interval, QRS duration, QT duration, PR duration, QTcF interval)

    The 12-lead electrocardiogram (ECG) result will be assessed including RR interval, QRS duration, QT duration, PR duration, and QTcF interval

    Time frame: Screening through Day 43

  7. Wound assessment by Numerical Pain Rating Scale (NPRS)

    The surgical site will be examined by the investigator using a 5-point numerical pain rating scale as follows: 1. Normal healing 2. Bruising, erythema, edema 3. Clear or hemoserous drainage 4. Evidence of cellulitis such as heat, spreading erythema, purulent discharge 5. Tissue breakdown, wound dehiscence, hematoma requiring aspiration

    Time frame: Day 1 through Day 43

  8. AUC of NPRS-R (0-10)

    AUC of NPRS-R (0-10)

    Time frame: 0-36, 0-48, 0-72, 0-96, 0-120,24-48, 48-72, 72-96, 96-120, and 120-168 hours

  9. Proportion of pain-free (NPRS-R of 0 or 1) subjects

    Proportion of pain-free (NPRS-R of 0 or 1) subjects

    Time frame: at 12, 24, 36, 48, 72, 96, 120, and 168 hours

  10. Proportion of subjects who used no rescue opioid analgesic

    Proportion of subjects who used no rescue opioid analgesic

    Time frame: through 12, 24, 36, 48, 72, 96, 120, and 168 hours

  11. Time to the first postoperative use of rescue opioid analgesics

    Time to the first postoperative use of rescue opioid analgesics

    Time frame: Day 1 to Day 43

  12. Total postoperative consumption of rescue opioid analgesics used

    Total postoperative consumption of rescue opioid analgesics used

    Time frame: through 24, 36, 48, 60, 72, 96, 120, and 168 hours

07

Study locations

5 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Chesapeake Research Group
    Pasadena, Maryland 21122-1020, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
  • JBR clinical research
    Draper, Utah 84020, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2020, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2019
First posted
Feb 12, 2019
StartActual
Mar 5, 2019
Primary completionActual
Mar 31, 2020
CompletionActual
Mar 31, 2020
Last update
Apr 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03838133
Lead sponsor
Taiwan Liposome Company
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Mar 5, 2019
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Last update
Apr 7, 2020

Study contacts

Carl Brown, PhD
study director · Taiwan Liposome Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion